Co-Diagnostics, Inc. (CODX)
- Previous Close
1.1600 - Open
1.1400 - Bid 0.8280 x 200
- Ask 1.4800 x 200
- Day's Range
1.1400 - 1.1700 - 52 Week Range
0.9750 - 1.8900 - Volume
18,402 - Avg. Volume
58,187 - Market Cap (intraday)
35.949M - Beta (5Y Monthly) -0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2000 - Earnings Date May 9, 2024 - May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.50
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
www.codiagnostics.comRecent News: CODX
Performance Overview: CODX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CODX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CODX
Valuation Measures
Market Cap
36.26M
Enterprise Value
-19.30M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.00
Price/Book (mrq)
0.42
Enterprise Value/Revenue
-2.83
Enterprise Value/EBITDA
0.47
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.44%
Return on Equity (ttm)
-35.24%
Revenue (ttm)
6.81M
Net Income Avi to Common (ttm)
-35.33M
Diluted EPS (ttm)
-1.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
58.55M
Total Debt/Equity (mrq)
3.48%
Levered Free Cash Flow (ttm)
-9.28M
Research Analysis: CODX
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell